Utility of d-dimer in the diagnosis of patients with chronic thromboembolic pulmonary hypertension
- PMID: 19572023
- PMCID: PMC2703202
- DOI: 10.2174/1874306400903010085
Utility of d-dimer in the diagnosis of patients with chronic thromboembolic pulmonary hypertension
Abstract
Background: Chronic thromboembolic pulmonary hypertension (CTEPH) is an important cause of severe pulmonary hypertension (PH). D-dimer, a degradation product of fibrin, has been used as a marker for various diseases. In patients with idiopathic pulmonary arterial hypertension there is evidence to suggest that D-dimer levels are associated with disease severity; however, data regarding D-dimer in patients with CTEPH are lacking.
Objective: To assess the significance of D-dimer in patients with CTEPH.
Patients and methods: Retrospective chart review of 618 patients seen at our PH clinic from 1991 to June 2008. Data collection focused on patients diagnosed with CTEPH, D-dimer levels, demographics, clinical, and hemodynamics. We compared D-dimer levels in CTEPH patients or World Health Organization (WHO) diagnostic group 4 with PH patients in WHO group 1.
Results: Thirty-four patients with confirmed CTEPH were identified, of these 19 had D-dimer levels and 7 were positive. Of the 234 patients in WHO group 1 excluding patients with portopulmonary hypertension (n = 54) and pulmonary venoocclusive disease (n = 2) 97 had D-dimer levels and 52 were positive. We found an estimated sensitivity of the D-dimer test in diagnosing CTEPH was 37% while the estimated specificity was 46%. The positive predictive value and negative predictive value were 12% and 79% respectively.
Conclusion: D-dimer is an insensitive and nonspecific test for the diagnosis of CTEPH. Despite a high negative predictive value D-dimer alone cannot be used to rule out CTEPH in patients with PH.
Similar articles
-
Platelets are highly activated in patients of chronic thromboembolic pulmonary hypertension.Arterioscler Thromb Vasc Biol. 2014 Nov;34(11):2486-94. doi: 10.1161/ATVBAHA.114.304404. Epub 2014 Aug 28. Arterioscler Thromb Vasc Biol. 2014. PMID: 25169936
-
[Features of clinical, functional and hemodynamics profile, medical treatment and prognosis evaluation in patients with inoperable chronic thromboembolic pulmonary hypertension and idiopathic pulmonary arterial hypertension according to the Russian registry].Ter Arkh. 2019 Sep 15;91(9):77-87. doi: 10.26442/00403660.2019.09.000343. Ter Arkh. 2019. PMID: 32598818 Russian.
-
Usefulness of thrombosis and inflammation biomarkers in chronic thromboembolic pulmonary hypertension-sampling plasma and surgical specimens.J Heart Lung Transplant. 2018 Sep;37(9):1067-1074. doi: 10.1016/j.healun.2018.04.003. Epub 2018 Apr 25. J Heart Lung Transplant. 2018. PMID: 29802084
-
Update on chronic thromboembolic pulmonary hypertension.Trends Cardiovasc Med. 2017 Jan;27(1):29-37. doi: 10.1016/j.tcm.2016.05.010. Epub 2016 May 25. Trends Cardiovasc Med. 2017. PMID: 27345156 Review.
-
Recent progress in the diagnosis and management of chronic thromboembolic pulmonary hypertension.Respir Investig. 2013 Sep;51(3):134-46. doi: 10.1016/j.resinv.2013.02.005. Epub 2013 Apr 30. Respir Investig. 2013. PMID: 23978639 Review.
Cited by
-
A nomogram model based on clinical and 3D-EIT parameters for CTEPH diagnosis.Respir Res. 2025 Apr 12;26(1):137. doi: 10.1186/s12931-025-03206-9. Respir Res. 2025. PMID: 40221785 Free PMC article.
-
High D-dimer plasma concentration in systemic sclerosis patients: Prevalence and association with vascular complications.J Scleroderma Relat Disord. 2021 Jun;6(2):178-186. doi: 10.1177/2397198320957558. Epub 2020 Sep 24. J Scleroderma Relat Disord. 2021. PMID: 35386738 Free PMC article.
-
Pulmonology approach in the investigation of chronic unexplained dyspnea.J Bras Pneumol. 2021 Feb 8;47(1):e20200406. doi: 10.36416/1806-3756/e20200406. eCollection 2021. J Bras Pneumol. 2021. PMID: 33567064 Free PMC article.
-
Platelet, Fibrinolytic and Other Coagulation Abnormalities in Newly-Diagnosed Patients with Chronic Thromboembolic Pulmonary Hypertension.Diagnostics (Basel). 2022 May 16;12(5):1238. doi: 10.3390/diagnostics12051238. Diagnostics (Basel). 2022. PMID: 35626393 Free PMC article.
-
Revisiting a Distinct Entity in Pulmonary Vascular Disease: Chronic Thromboembolic Pulmonary Hypertension (CTEPH).Medicina (Kaunas). 2021 Apr 7;57(4):355. doi: 10.3390/medicina57040355. Medicina (Kaunas). 2021. PMID: 33916978 Free PMC article. Review.
References
-
- Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. N Engl J Med. 2001;345:1465–72. - PubMed
-
- Tapson VF, Humbert M. Incidence and prevalence of chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc. 2006;3:564–7. - PubMed
-
- Becattini C, Agnelli G, Pesavento R, et al. Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. Chest. 2006;130:172–75. - PubMed
-
- Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004;350:2257–64. - PubMed
LinkOut - more resources
Full Text Sources